Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

Biology and Pathology: Decoding the Tumor Fingerprint

At a Glance

In neuroblastoma, a tumor's biological fingerprint dictates its risk level and treatment. The most critical marker is MYCN amplification, which signals an aggressive, high-risk tumor. Pathologists also evaluate cell maturity and growth rate to classify the tumor as favorable or unfavorable.

While imaging tells us where the tumor is, the pathology and biology reports tell us what the tumor is actually made of. These reports are like a “genetic fingerprint” of the cancer, helping doctors predict how the disease might behave and how aggressively it needs to be treated [1][2].

The Most Critical Marker: MYCN Amplification

The most important biological factor in neuroblastoma is a gene called MYCN [3]. Every cell has this gene, but in about 20% of neuroblastoma cases, the tumor cells have hundreds of extra copies of it [4][5]. This is called MYCN amplification (MNA).

When MYCN is amplified, it acts like an “on switch” that never turns off, telling the cancer cells to grow and divide rapidly [6][7]. Because of this, tumors with MYCN amplification are automatically classified as high-risk, regardless of the child’s age or the tumor’s stage [1][3].

Segmental Chromosomal Aberrations (SCAs)

Chromosomes are the structures that hold our DNA. In neuroblastoma, doctors look for specific “broken” or “missing” pieces of these chromosomes, known as Segmental Chromosomal Aberrations (SCAs) [8]. These are different from “numerical” changes, where a cell simply has the wrong number of whole chromosomes (which is often a better sign) [9].

Key SCAs include:

  • 1p Deletion: A piece of chromosome 1 is missing. This is often seen alongside MYCN amplification and is linked to a more aggressive disease course [8][10].
  • 11q Loss: A piece of chromosome 11 is missing. This is typically found in tumors without MYCN amplification and is an important marker for risk in older children [10][11].
  • 17q Gain: An extra piece of chromosome 17 is present. This is a common finding in neuroblastoma and is often an early sign of chromosomal instability [12].

Decoding the Pathology: Favorable vs. Unfavorable

When a pathologist looks at the tumor cells under a microscope, they use the International Neuroblastoma Pathology Classification (INPC), also known as the Shimada criteria, to label the histology as either “favorable” or “unfavorable” [13][14].

This classification is based on three main factors:

  1. Degree of Maturation: How much the cancer cells look like normal, mature nerve cells [13].
  2. Mitosis-Karyorrhexis Index (MKI): A measure of how many cells are actively dividing (mitosis) or dying (karyorrhexis) [15][16]. A High MKI means the tumor is growing very quickly [17].
  3. Age at Diagnosis: The same cellular features might be considered “favorable” in an infant but “unfavorable” in a 3-year-old [14][18].

Favorable Histology (FH) usually means the tumor is growing slowly and looks more like mature tissue [13]. Unfavorable Histology (UH) means the tumor cells are “undifferentiated” (very immature) and dividing rapidly, requiring more intensive therapy [13][19].

Emerging Markers: ALK and ATRX

Recent research has identified other important markers, such as ALK and ATRX [20].

  • ALK Mutations: Found in about 10-15% of cases, these mutations can sometimes be targeted with specific drugs called ALK inhibitors [21][22].
  • ATRX Mutations: More common in older children and adolescents, these mutations affect how the tumor maintains its DNA [23][24].

Understanding these terms can be overwhelming, but they are the tools your oncology team uses to build the most precise and effective treatment plan for your child [1][25].

Return to the Home Page.

Common questions in this guide

What does MYCN amplification mean for my child's neuroblastoma?
MYCN amplification means the neuroblastoma cells have hundreds of extra copies of the MYCN gene, acting like an "on switch" for rapid growth. Tumors with this genetic marker are automatically classified as high-risk and require more intensive treatment.
What is the difference between favorable and unfavorable histology?
Favorable histology means the tumor is growing slowly and its cells look more like mature tissue. Unfavorable histology indicates the cells are very immature and dividing rapidly, which typically requires a more aggressive treatment approach.
What does a high MKI score mean on a pathology report?
The Mitosis-Karyorrhexis Index (MKI) measures how many cells in the tumor are actively dividing or dying. A high MKI score on your child's pathology report indicates that the tumor is growing very quickly.
What are Segmental Chromosomal Aberrations (SCAs)?
Segmental Chromosomal Aberrations are missing or extra pieces of chromosomes, such as a 1p deletion or 11q loss. Doctors use these specific DNA changes to help predict how aggressively the tumor might behave.
How do ALK mutations affect treatment options?
ALK mutations are genetic changes found in about 10-15% of neuroblastoma cases. If this mutation is present in your child's tumor, the oncology team may be able to target it with specific drugs called ALK inhibitors.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the MYCN gene in my child's tumor 'amplified' or 'non-amplified'?
  2. 2.Does the pathology report show 'favorable' or 'unfavorable' histology?
  3. 3.Were any specific segmental chromosomal aberrations, like 1p deletion or 11q loss, identified?
  4. 4.What was the Mitosis-Karyorrhexis Index (MKI) score for the tumor?
  5. 5.Are there any mutations in the ALK gene that might change our treatment options?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

    Liang WH, Federico SM, London WB, et al.

    JCO clinical cancer informatics 2020; (4()):895-905 doi:10.1200/CCI.20.00074.

    PMID: 33058692
  2. 2

    Exosomes from Plasma of Neuroblastoma Patients Contain Doublestranded DNA Reflecting the Mutational Status of Parental Tumor Cells.

    Degli Esposti C, Iadarola B, Maestri S, et al.

    International journal of molecular sciences 2021; (22(7)) doi:10.3390/ijms22073667.

    PMID: 33915956
  3. 3

    Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.

    Lee JW, Son MH, Cho HW, et al.

    Pediatric blood & cancer 2018; (65(10)):e27257 doi:10.1002/pbc.27257.

    PMID: 29797634
  4. 4

    Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.

    Hallett RM, Seong AB, Kaplan DR, Irwin MS

    Molecular oncology 2016; (10(9)):1461-1472 doi:10.1016/j.molonc.2016.07.012.

    PMID: 27599694
  5. 5

    Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

    Campbell K, Shyr D, Bagatell R, et al.

    Pediatric blood & cancer 2019; (66(8)):e27819 doi:10.1002/pbc.27819.

    PMID: 31115156
  6. 6

    A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.

    Li HL, Dong LL, Jin MJ, et al.

    Molecules (Basel, Switzerland) 2023; (28(3)) doi:10.3390/molecules28031141.

    PMID: 36770809
  7. 7

    Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

    Campbell K, Gastier-Foster JM, Mann M, et al.

    Cancer 2017; (123(21)):4224-4235 doi:10.1002/cncr.30873.

    PMID: 28696504
  8. 8

    Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

    Bosse KR, Maris JM

    Cancer 2016; (122(1)):20-33 doi:10.1002/cncr.29706.

    PMID: 26539795
  9. 9

    Chromosome instability in neuroblastoma.

    Fusco P, Esposito MR, Tonini GP

    Oncology letters 2018; (16(6)):6887-6894 doi:10.3892/ol.2018.9545.

    PMID: 30546420
  10. 10

    Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without MYCN amplification.

    Wieczorek A, Szewczyk K, Klekawka T, et al.

    Frontiers in oncology 2023; (13()):1134772 doi:10.3389/fonc.2023.1134772.

    PMID: 36865795
  11. 11

    Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

    Pinto N, Mayfield JR, Raca G, et al.

    Pediatric blood & cancer 2016; (63(6)):1019-23 doi:10.1002/pbc.25934.

    PMID: 26864375
  12. 12

    Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progression.

    Milosevic J, Fransson S, Svensson J, et al.

    Cancer letters 2025; (625()):217769 doi:10.1016/j.canlet.2025.217769.

    PMID: 40320038
  13. 13

    Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.

    Shimada H, Ikegaki N

    Biomolecules 2022; (12(1)) doi:10.3390/biom12010079.

    PMID: 35053227
  14. 14

    [An update on the pathology of peripheral neuroblastic tumors].

    Gengler C, Boudjemaa S, Gazeu A, Sartelet H

    Annales de pathologie 2025; doi:10.1016/j.annpat.2025.06.025.

    PMID: 40835512
  15. 15

    MIB-1 Index as a Surrogate for Mitosis-Karyorrhexis Index in Neuroblastoma.

    Atikankul T, Atikankul Y, Santisukwongchote S, et al.

    The American journal of surgical pathology 2015; (39(8)):1054-60 doi:10.1097/PAS.0000000000000478.

    PMID: 26171918
  16. 16

    Mitosis-Karyorrhexis Index evaluation by digital image visual analysis for application of International Neuroblastoma Pathology Classification in FNA biopsy.

    Bhardwaj N, Rohilla M, Trehan A, et al.

    Cancer cytopathology 2022; (130(2)):128-135 doi:10.1002/cncy.22520.

    PMID: 34633743
  17. 17

    MYCN amplification and International Neuroblastoma Risk Group stratification on fine-needle aspiration biopsy and their correlation to survival in neuroblastoma.

    Bhardwaj N, Rohilla M, Trehan A, et al.

    Journal of clinical pathology 2023; (76(9)):599-605 doi:10.1136/jclinpath-2022-208177.

    PMID: 35414524
  18. 18

    Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

    Sokol E, Desai AV, Applebaum MA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(17)):1906-1918 doi:10.1200/JCO.19.03285.

    PMID: 32315273
  19. 19

    Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.

    Nakazawa A

    Pathology international 2021; (71(4)):232-244 doi:10.1111/pin.13085.

    PMID: 33657257
  20. 20

    Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma.

    Mansfield SA, McCarville MB, Lucas JT, et al.

    Annals of surgical oncology 2022; (29(1)):661-670 doi:10.1245/s10434-021-10386-3.

    PMID: 34215956
  21. 21

    Differential Impact of ALK Mutations in Neuroblastoma.

    O'Donohue T, Gulati N, Mauguen A, et al.

    JCO precision oncology 2021; (5()) doi:10.1200/PO.20.00181.

    PMID: 34250410
  22. 22

    Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.

    Pastorino F, Capasso M, Brignole C, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030560.

    PMID: 36765519
  23. 23

    MYCN amplification and ATRX mutations are incompatible in neuroblastoma.

    Zeineldin M, Federico S, Chen X, et al.

    Nature communications 2020; (11(1)):913 doi:10.1038/s41467-020-14682-6.

    PMID: 32060267
  24. 24

    Immunohistochemistry for ATRX Can Miss ATRX Mutations: Lessons From Neuroblastoma.

    Chami R, Marrano P, Teerapakpinyo C, et al.

    The American journal of surgical pathology 2019; (43(9)):1203-1211 doi:10.1097/PAS.0000000000001322.

    PMID: 31290759
  25. 25

    Independent Prognostic Factors and Nomogram Prediction of Cancer-Specific Survival in Postoperative Patients With Spinal Cord Astrocytoma.

    Wang Y, Jiao J, Yu T, et al.

    Global spine journal 2025; (15(2)):370-381 doi:10.1177/21925682231191094.

    PMID: 37498194

This page explains neuroblastoma pathology terminology for educational purposes only. Your pediatric oncologist and pathologist are the best sources for interpreting your child's specific pathology report.

Get notified when new evidence is published on Neuroblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.